Trial Type
First-Line-Therapy (Metastatic Disease/Hematology)
Description for experts
Ph+ ALL, ponatinib compared to imatinib in combination with low-intensity chemotherapy, to compare end of therapy with indication for SCT with TKI in combination with blinatumomab and chemotherapy in optimal response and to assess blinatumomab before SCT in suboptimal response
Description for laymen
Ph+ ALL, ponatinib compared to imatinib in combination with low-intensity chemotherapy, to compare end of therapy with indication for SCT with TKI in combination with blinatumomab and chemotherapy in optimal response and to assess blinatumomab before SCT in suboptimal response
JSON Data
{
"short_title": "GMALL-EVOLVE",
"data_mode": "910",
"data_mode_number": "000000023",
"official_title": null,
"accrual_state": "running",
"therapeutic_value": "not_applicable",
"therapieansatz_value": "not_applicable",
"therapieintervention_value": "not_applicable",
"therapielinie_value": "first",
"ctgov_number": null,
"eudract_number": "2022-000760-21",
"general_contact_email": "sal-aml-register@ukdd.de",
"general_contact_phone": "+49 351-45818380",
"hauptpruefer_dd_name": null,
"description_laie_de": "Ph+ ALL, Ponatinib im Vergleich zu Imatinib in Kombination mit niedrig-intensiver Chemotherapie, zum Vergleich des Endes der Therapie mit Indikation zur SZT mit TKI in Kombination mit Blinatumomab und Chemotherapie bei optimalem Ansprechen und zur Beurteilung von Blinatumomab vor SZT bei suboptimalem Ansprechen",
"description_laie_en": "Ph+ ALL, ponatinib compared to imatinib in combination with low-intensity chemotherapy, to compare end of therapy with indication for SCT with TKI in combination with blinatumomab and chemotherapy in optimal response and to assess blinatumomab before SCT in suboptimal response",
"description_expert_de": "Ph+ ALL, Ponatinib im Vergleich zu Imatinib in Kombination mit niedrig-intensiver Chemotherapie, zum Vergleich des Endes der Therapie mit Indikation zur SZT mit TKI in Kombination mit Blinatumomab und Chemotherapie bei optimalem Ansprechen und zur Beurteilung von Blinatumomab vor SZT bei suboptimalem Ansprechen",
"description_expert_en": "Ph+ ALL, ponatinib compared to imatinib in combination with low-intensity chemotherapy, to compare end of therapy with indication for SCT with TKI in combination with blinatumomab and chemotherapy in optimal response and to assess blinatumomab before SCT in suboptimal response",
"rechtsgrundlage_value": null,
"phase_amg_value": null,
"main_cat_id": 4,
"sub_cat_id": 31
}
